CHAARTED: ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer [CHAARTED].

Trial Profile

CHAARTED: ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer [CHAARTED].

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 31 Jan 2018

At a glance

  • Drugs Docetaxel (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms CHAARTED
  • Most Recent Events

    • 31 Jan 2018 Primary endpoint (Overall Survival) has been met as per the results published in the Journal of Clinical Oncology
    • 31 Jan 2018 Results of updated survival analysis (cutoff date April 23, 2016) assessing efficacy and safety published in the Journal of Clinical Oncology
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top